Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy

Aman U. Buzdar, Charles K. Tashima, George R. Blumenschein, Gabriel N. Hortobagyi, Hwee‐Yong ‐Y Yap, Allan N. Krutchik, Gerald P. Bodey, Robert B. Livingston

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin‐C 20 mg/m2 I.V. every 4–6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non‐responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non‐responders was statistically significant at p<0.01 level. Attenuated doses of mitomycin‐C were administered at increasing intervals due to cumulative myelosuppressive toxicity.

Original languageEnglish (US)
Pages (from-to)392-395
Number of pages4
JournalCancer
Volume41
Issue number2
DOIs
StatePublished - Feb 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy'. Together they form a unique fingerprint.

  • Cite this